Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Editas Competitor CRISPR Therapeutics Hails European Patent Decision

Executive Summary

CRISPR Therapeutics says its IP position has been reinforced by the European Patent Office's aim to grant the University of California patent recognition covering CRISPR gene-editing for non-cellular and cellular use.

Advertisement

Related Content

Editas' EDIT-101 Set To Be First In Vivo CRISPR Gene-Editing Therapy In Clinic
India’s Stem Cell Guidelines Mandate Additional Checks
Merck Develops 'New And Improved' CRISPR
UC's CRISPR Licensees Unbowed By Losing Initial US Patent Office Ruling
Head of Bayer LifeScience Center: Expect More JVs

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC098475

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel